SLNO - カプニア (Soleno Therapeutics Inc.)

SLNOのニュース

   ORGS, SLNO, CDTX, BLPH, ARCT added to Indexes (NASDAQ:ORGS)  2020/06/29 12:25:02 Seeking Alpha
Orgenesis (NASDAQ:ORGS) added to the Russell 3000 Index, effective after the market open June 29. Soleno Therapeutics (NASDAQ:SLNO) added to the Russell 30
   Soleno Therapeutics Added to Russell 3000® Index  2020/06/29 12:00:00 GlobeNewswire
REDWOOD CITY, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company…
   Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock  2020/06/24 12:31:27 GlobeNewswire
REDWOOD CITY, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage…
   Soleno Plunging 48% In Pre-Market On Obesity Study Failure  2020/06/09 10:12:03 Smarter Analyst
Shares in Soleno Therapeutics, Inc. (SLNO) are plunging over 45% in Tuesday’s pre-market trading after the company announced disappointing top-line results from its … The post Soleno Plunging 48% In Pre-Market On Obesity Study Failure appeared first on Smarter Analyst .
   Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options  2020/06/01 12:37:00 Zacks Investment Research
Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.
   Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study  2020/01/07 09:21:00 Zacks Investment Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
   Soleno Therapeutics Inc (NASDAQ:SLNO) Expected to Post Earnings of -$0.17 Per Share  2019/11/08 11:14:51 Modern Readers
Analysts expect Soleno Therapeutics Inc (NASDAQ:SLNO) to announce earnings of ($0.17) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings per share of ($0.11) in the same quarter last year, which indicates a negative year over year growth rate […]
   Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know  2019/07/15 13:00:07 Zacks Investment Research
Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Soleno Therapeutics beats by $0.07  2019/05/13 12:06:36 Seeking Alpha
   Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?  2019/05/06 20:13:00 Zacks Investment Research
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.
   Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study  2020/01/07 09:21:00 Zacks Investment Research
Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.
   Soleno Therapeutics Inc (NASDAQ:SLNO) Expected to Post Earnings of -$0.17 Per Share  2019/11/08 11:14:51 Modern Readers
Analysts expect Soleno Therapeutics Inc (NASDAQ:SLNO) to announce earnings of ($0.17) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings per share of ($0.11) in the same quarter last year, which indicates a negative year over year growth rate […]
   Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know  2019/07/15 13:00:07 Zacks Investment Research
Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Soleno Therapeutics beats by $0.07  2019/05/13 12:06:36 Seeking Alpha
   Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?  2019/05/06 20:13:00 Zacks Investment Research
During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

calendar